News
Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...
Hosted on MSN22d
Eli Lilly strikes $1.3bn gene therapy deal with RznomicsEli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback